In This Article:
Bristol-Myers Squibb (NYSE:BMY) First Quarter 2025 Results
Key Financial Results
-
Revenue: US$11.2b (down 5.6% from 1Q 2024).
-
Net income: US$2.46b (up from US$11.9b loss in 1Q 2024).
-
Profit margin: 22% (up from net loss in 1Q 2024).
-
EPS: US$1.21 (up from US$5.89 loss in 1Q 2024).
Our free stock report includes 3 warning signs investors should be aware of before investing in Bristol-Myers Squibb. Read for free now.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Bristol-Myers Squibb Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 4.6%. Earnings per share (EPS) missed analyst estimates by 3.8%.
Looking ahead, revenue is expected to decline by 4.9% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 8.8%.
Performance of the American Pharmaceuticals industry.
The company's shares are down 2.7% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 3 warning signs for Bristol-Myers Squibb you should know about.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.